What is ivonescimab, and how does it work?
Ivonescimab (also called AK112 or SMT112) is a bispecific antibody targeting PD-1 and VEGF. It helps the immune system act against cancer while blocking a signal involved in tumor blood-vessel formation. The approved treatment settings described here concern non-small cell lung cancer (NSCLC).
The practical question is: would I receive it alone or with chemotherapy? Pathology, driver-gene results, PD-L1 and previous treatment determine which option is relevant. Start with the patient groups below, then compare the evidence, costs and arrangements.
Source [1]
Where is it approved, and who can receive it?
China has approved the following three treatment settings. Use these to identify the relevant pathway; the treating specialist checks the full indication and your health before prescribing.
| Patient situation | Regimen and China approval |
|---|---|
| EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC after EGFR-TKI treatment | Ivonescimab plus chemotherapy; May 2024 |
| PD-L1 TPS ≥1%, EGFR/ALK-negative advanced NSCLC, starting first-line treatment | Ivonescimab alone; April 2025 |
| Advanced squamous NSCLC, starting first-line treatment | Ivonescimab plus chemotherapy; August 2026 |
What does approval in China mean for international patients?
These indications first reached approval in China, while the international regulatory program continues. The distinction is specific: a patient who meets one of these labels may have an approved treatment route there before the same product is licensed in their home country. Histology, PD-L1 expression, driver alterations and previous treatment determine which route is relevant.
The US application for ivonescimab plus chemotherapy after EGFR-TKI treatment remains a separate regulatory decision. Summit reports an FDA target decision date of November 14, 2026; an accepted application and a scheduled date are not approval. This explains the present access difference without assuming the outcome of that review.
How does it compare with other treatments?
The randomized Phase III HARMONi-2 study compared ivonescimab with pembrolizumab as first-line treatment in PD-L1-positive advanced NSCLC in China. The published primary analysis reported median progression-free survival of 11.1 versus 5.8 months, measuring time before progression or death.
At WCLC in September 2026, a prespecified interim overall-survival analysis also reported a benefit: median overall survival was 30.8 versus 22.6 months. This is a later conference update, distinct from the earlier published progression-free-survival analysis.
For treatment planning, match the study population to the pathology, PD-L1 result and treatment history. The relevant choice may be an antibody alone or a complete chemotherapy combination, depending on the clinical setting.
| Study | Population and comparison |
|---|---|
| HARMONi-2 | Untreated, PD-L1-positive, EGFR/ALK-negative NSCLC; ivonescimab versus pembrolizumab alone. |
| Global HARMONi | EGFR-mutated disease after an EGFR-TKI; ivonescimab plus chemotherapy versus chemotherapy. These are not the HARMONi-2 patients. |
What do these results mean for my decision?
Match the patient group before comparing treatments. HARMONi-2 compares two single drugs in a defined first-line population; it does not establish superiority over every lung-cancer regimen. If your cancer has progressed after an EGFR-targeted drug and a chemotherapy combination is being considered, the relevant study is different. Median survival describes a study population, not your individual expected outcome.
Could it fit my diagnosis and treatment history?
Confirm squamous versus nonsquamous histology, comprehensive driver testing where appropriate, PD-L1 TPS and the treatment sequence. Patients with an EGFR mutation after targeted treatment face a different decision from patients considering first-line immunotherapy. Brain metastases, bleeding risk and the need for a rapid response may also affect the plan.
Four questions for your specialist review
- What does the pathology show? Send the original report, including squamous or nonsquamous subtype, stage and known metastatic sites—not just a diagnosis name.
- Which biomarker results are available? Include complete driver-gene and PD-L1 reports with test dates and sample details. If a result is missing, the specialist can identify whether further testing is needed.
- What has already been tried? List each medicine, start and stop dates, response and reason for stopping. After progression on Tagrisso (osimertinib), include the latest scan and any repeat testing; progression alone does not establish that ivonescimab is the right next treatment.
- What could affect treatment safety? Describe current symptoms, previous immune-treatment side effects, bleeding history, other illnesses, regular medicines and any planned surgery.
Match the whole regimen to the report
PD-L1 positivity does not override an actionable driver alteration. Confirm whether the proposal is monotherapy or a chemotherapy combination, which histology it covers and where it belongs in the treatment sequence. Previous immune toxicity and anti-angiogenic exposure should be documented rather than summarized as “previous immunotherapy.”
What does treatment involve, and what are the risks?
Treatment is given by intravenous infusion, alone or with chemotherapy according to the indication. Monitoring must cover immune-related inflammation and VEGF-pathway effects such as hypertension, proteinuria and bleeding, as well as chemotherapy toxicity when combined. New breathlessness, significant bleeding, severe diarrhea or other acute symptoms require prompt contact with the treating team.
Plan monitoring before the first infusion
- Baseline: discuss blood pressure, urine protein, bleeding history and planned surgery with the team.
- Between cycles: keep an accessible symptom record and an urgent contact route; immune inflammation and vascular complications need different assessments.
- At review: compare imaging, symptoms and tolerability together; continuing treatment is a clinical decision, not an automatic repeat booking.
How much could treatment cost?
US$13,000–58,000
What’s included
This estimate covers total medical treatment costs, including medication, specialist consultations and assessment, pretreatment tests, routine laboratory and imaging follow-up, treatment administration and nursing, necessary hospitalization and monitoring, and routine supportive care. Travel and accommodation are not included.
Serious complications, ICU care or additional anticancer treatments may incur separate costs. Confirm coordination-service fees separately in the written estimate.
Your individual treatment costs
Most ongoing drug treatments do not have a fixed treatment duration, and costs accumulate with the number of treatments received. Your prescribed dose, combination therapies and care needs also affect the total. This range is indicative only; your individual costs may fall outside it. Contact us for a personalized cost estimate based on your medical needs and specialist assessment.
Before booking, we help clarify the regimen, expected treatment visits, tests and hospital stays, and obtain a written medical cost estimate for your budget. The range shown is not a fixed-course package or a spending cap.
How can Chirona arrange my care?
Start with a records review before committing to travel. Chirona arranges assessment with relevant specialists at partner hospitals and turns the agreed medical plan into practical care arrangements.
1. Prepare records and arrange specialist review
Send pathology, biomarker results, recent imaging and a dated treatment history. We organize the records, coordinate language needs and arrange review at a partner hospital to clarify suitability, missing tests and alternatives for your situation.
2. Confirm the center, plan and costs before travel
Once a plan is agreed, we coordinate the treating center, appointments, a written medical cost estimate, language support and travel. Before departure, clarify whether treatment is alone or combined, planned visits, any hospital stay and outstanding pretreatment tests.
3. Plan monitoring and follow-up at home
Confirm scan and laboratory follow-up, whom to contact about symptoms and where later infusions will take place. We help organize treatment records for your home team. Further treatment is planned after reviewing response and tolerability.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.